A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Obiltoxaximab (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors EluSys Therapeutics
- 14 Sep 2016 According to an Elusys Therapeutics media release, results from this study are published online at Clinical Therapeutics.
- 24 Aug 2016 Results assessing safety, immunogenicity, and pharmacokinetics of this and other four studies published in the Clinical Therapeutics.
- 02 Aug 2012 The trial enrolled a total of 108 patients according to an EluSys Therapeutics media release.